SYnAbs' vision is to fill the gap on the marketplace for innovative mAbs against poor immunogenic compounds and complex antigens. Targeting steroids, peptides, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.
SYnAbs was set up in September 2015 out of Professor Pierre Gianellos experimental surgery laboratory (CHEX) in order to develop greater expertise in the custom production of monoclonal antibodies, of rats but also of guinea pigs. The UCL spin-off was set up as a result of coordinated action by the laboratory, the Louvain Technology Transfer Office (LTTO), Wallonia Biotech Coaching and a French group, Biotech Investissement (which owns RD Biotech and Diaclone companies).
The equity investment by Biotech Investissement (based in Besançon, France) was decisive in validating the business plan. This group provides services to biopharmaceutical companies and produces custom monoclonal antibodies. The complementary nature of the two entities, SYnAbs and Biotech Investissement, will make it possible to consolidate SYnAbss activity in Belgium and to expand its sales network in France and the Netherlands. This partnership, the key element in setting up the spin-off, was also possible thanks to the partnership between the LTTO and Wallonia Biotech Coaching (WBC), the incubator for life sciences in Wallonia. Thanks to WBC, the SYnAbs project has benefited from the CxO measure for «orphan» projects which meant that a business mentor could be recruited for the final phases of setting up the company. The work by Didier Argentin, the business mentor assigned by WBC to SYnAbs and now the CEO of the spin-off, was decisive in establishing the collaboration with Biotech Investissement.
SYnAbs SA is currently involved in the production of rat monoclonal antibodies, serving CROs (mAb and custom immunoassays) and with a large catalogue of secondary monoclonal antibodies (more than a hundred secondary anti-immunoglobulins) and unique primary monoclonal antibodies has gained strong international recognition which its founders wish to increase further.
Thanks to its scientists led by their CSO Yannick Nizet, PhD, as well as the broad biotechnology support offered by its sister companies Rd-Biotech and Diaclone, France, SynAbs can indeed present a one-stop-shop portfolio of services, covering the antigen synthesis and the hapten-carriers chemistry, through the parallel immunisation of mice, rats and guinea pigs, up to the custom generation and manufacturing of gram levels of these mouse, rat and guinea pigs monoclonal antibodies.
This unique triple immunisation platform enables SynAbs to increase the probability getting the unique monoclonal youre looking for, and therefore maximizes the success rate of
our clients !
SynAbs has currently 130 m2 of production laboratories and generates earnings of 1 million euro.
Discover our first press release in English, French and Dutch.